tetano
Editor, Senior Moderator
J Infect Chemother
. 2020 Aug 6;S1341-321X(20)30271-3.
doi: 10.1016/j.jiac.2020.08.001. Online ahead of print.
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
Sho Iwasaka[SUP] 1 [/SUP], Yuji Shono[SUP] 2 [/SUP], Kentaro Tokuda[SUP] 2 [/SUP], Kosuke Nakashima[SUP] 2 [/SUP], Yuzo Yamamoto[SUP] 2 [/SUP], Jun Maki[SUP] 2 [/SUP], Yoji Nagasaki[SUP] 3 [/SUP], Nobuyuki Shimono[SUP] 4 [/SUP], Tomohiko Akahoshi[SUP] 2 [/SUP], Tomoaki Taguchi[SUP] 2 [/SUP]
Affiliations
Abstract
The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.
Keywords: COVID-19; Continuous hemodiafiltlation; Hydroxychloroquine; Nafamostat mesylate; SARS-CoV-2.
. 2020 Aug 6;S1341-321X(20)30271-3.
doi: 10.1016/j.jiac.2020.08.001. Online ahead of print.
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
Sho Iwasaka[SUP] 1 [/SUP], Yuji Shono[SUP] 2 [/SUP], Kentaro Tokuda[SUP] 2 [/SUP], Kosuke Nakashima[SUP] 2 [/SUP], Yuzo Yamamoto[SUP] 2 [/SUP], Jun Maki[SUP] 2 [/SUP], Yoji Nagasaki[SUP] 3 [/SUP], Nobuyuki Shimono[SUP] 4 [/SUP], Tomohiko Akahoshi[SUP] 2 [/SUP], Tomoaki Taguchi[SUP] 2 [/SUP]
Affiliations
- PMID: 32893123
- DOI: 10.1016/j.jiac.2020.08.001
Abstract
The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.
Keywords: COVID-19; Continuous hemodiafiltlation; Hydroxychloroquine; Nafamostat mesylate; SARS-CoV-2.